Adagene Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
China CN
Employees
128
IPO date
Feb 9, 2021

Adagene is a biotechnology company that designs and develops antibody-based cancer medicines. Its main work is to create therapeutic antibodies and move the most promising ones into clinical testing, rather than selling a finished drug portfolio today. The company’s science centers on making antibodies that are active only when they reach the right tumor environment, which is meant to improve how the drugs target cancer cells.

Its customers are mainly pharmaceutical partners, and eventually patients and doctors if its drug candidates win approval. Adagene makes money through collaboration deals, research partnerships, licensing arrangements, and, in the longer run, could earn product sales or royalties if any of its drug programs reach the market. That means the business is built around drug discovery and development, not manufacturing a large consumer product.

What makes Adagene different is its focus on precision antibody engineering. Instead of inventing a broad range of medicines, it concentrates on one technical problem: making powerful antibodies safer and more selective by controlling when and where they turn on. In the biotech value chain, that puts Adagene in the early-stage research and development role, where its main assets are its platform, its drug candidates, and its partnerships with larger drug companies.

Adagene Inc Investor Relations

Address
4F, Building C14,218 Xinghu St., Suzhou Industrial Park
Suzhou, Jiangsu
China

Business Segments

Antibody therapeutics

Adagene discovers and develops engineered antibody drugs for cancer and other diseases, mainly through its own pipeline of experimental medicines and its antibody platform.

Customers and revenue model

Management

Dr. Peter P. Luo Ph.D.

Co- Founder, Chairman, CEO and President of R&D

Biography unavailable

Mr. Man Kin Tam M.B.A.

CFO & Director

Biography unavailable

Dr. Jc Xu M.D., Ph.D.

Chief Scientific Officer

Biography unavailable

Ms. Ami Celeste Knoefler

Vice President of Investor Relations & Corporate Communications

Biography unavailable

Ms. Ling Zhou

Head of Human Resources

Biography unavailable

Dr. Qinghai Zhao

Chief Manufacturing Officer

Biography unavailable

Ms. Yan Li M.B.A.

Senior Vice President of Bioinformatics & Information Technology

Biography unavailable

Ms. Xiaohong She

Senior VP & Head of Clinical Operations

Biography unavailable

Dr. Guizhong Liu Ph.D.

Senior Vice President of Early Drug Discovery

Biography unavailable

Mr. Alexander Goergen

VP & Head of Business Development

Biography unavailable

1 / 10